	US 12,251,427 B2
	Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
Jason Joseph Rose, Pittsburgh, PA (US); Qinzi Xu, Wexford, PA (US); Mark T. Gladwin, Pittsburgh, PA (US); and Jesus Tejero Bravo, Pittsburgh, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Mar. 17, 2021, as Appl. No. 17/204,625.
Application 17/204,625 is a continuation of application No. 16/302,324, granted, now 10,973,883, previously published as PCT/US2017/033607, filed on May 19, 2017.
Claims priority of provisional application 62/338,870, filed on May 19, 2016.
Prior Publication US 2021/0205419 A1, Jul. 8, 2021
Int. Cl. A61K 38/42 (2006.01); A61K 9/127 (2006.01); A61K 35/14 (2015.01); C01C 3/08 (2006.01); C07K 14/795 (2006.01); A61K 31/409 (2006.01); A61K 33/00 (2006.01); A61K 38/06 (2006.01)

CPC A61K 38/42 (2013.01) [A61K 9/127 (2013.01); A61K 35/14 (2013.01); C01C 3/08 (2013.01); C07K 14/795 (2013.01); A61K 31/409 (2013.01); A61K 33/00 (2013.01); A61K 38/063 (2013.01)]

7 Claims

1. A method of treating carboxyhemoglobinemia in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising an artificial oxygen carrier, wherein:

the artificial oxygen carrier has been contacted with a strong reducing agent to place the artificial oxygen carrier in the reduced form, wherein the strong reducing agent is removed therefrom prior to administration;

the artificial oxygen carrier is a modified hemoglobin;

the subject has at least 5% carboxyhemoglobin in their blood; and

the therapeutically effective amount of the composition scavenges carbon monoxide from carboxyhemoglobin in the blood or tissues of the subject, thereby reducing the level of carboxyhemoglobin in the blood or tissues of the subject.